183 related articles for article (PubMed ID: 35880341)
1. [Clinical research progress and implications of therapeutic vaccines for cervical cancer and precancerous lesions: a qualitative systematic review].
Cai S; Miao K; Tan XY; Cheng S; Li DT; Zeng XY; Yang Y; Meng RR; Liu ZK; Li Y; Li KL; Sun F; Zhan SY
Zhonghua Zhong Liu Za Zhi; 2022 Jul; 44(7):743-760. PubMed ID: 35880341
[No Abstract] [Full Text] [Related]
2. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.
Rambout L; Hopkins L; Hutton B; Fergusson D
CMAJ; 2007 Aug; 177(5):469-79. PubMed ID: 17671238
[TBL] [Abstract][Full Text] [Related]
4. [Global guidelines for cervical cancer and precancerous lesions treatment: a systematic review].
Zhao S; Chen H; Zhao FH
Zhonghua Yi Xue Za Zhi; 2022 Jun; 102(22):1666-1676. PubMed ID: 35692019
[No Abstract] [Full Text] [Related]
5. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus.
Corona Gutierrez CM; Tinoco A; Navarro T; Contreras ML; Cortes RR; Calzado P; Reyes L; Posternak R; Morosoli G; Verde ML; Rosales R
Hum Gene Ther; 2004 May; 15(5):421-31. PubMed ID: 15144573
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and Safety of Therapeutic Vaccines for Precancerous Cervical Lesions: A Systematic Review and Meta-Analysis.
Cai S; Tan X; Miao K; Li D; Cheng S; Li P; Zeng X; Sun F
Front Oncol; 2022; 12():918331. PubMed ID: 35734598
[TBL] [Abstract][Full Text] [Related]
7. Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics.
Pomfret TC; Gagnon JM; Gilchrist AT
J Clin Pharm Ther; 2011 Feb; 36(1):1-9. PubMed ID: 21198715
[TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus vaccine and cervical cancer prevention: practice and policy implications for pharmacists.
McIntosh J; Sturpe DA; Khanna N
J Am Pharm Assoc (2003); 2008; 48(1):e1-13; quiz e14-7. PubMed ID: 18192123
[TBL] [Abstract][Full Text] [Related]
9. Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine.
García-Hernández E; González-Sánchez JL; Andrade-Manzano A; Contreras ML; Padilla S; Guzmán CC; Jiménez R; Reyes L; Morosoli G; Verde ML; Rosales R
Cancer Gene Ther; 2006 Jun; 13(6):592-7. PubMed ID: 16456551
[TBL] [Abstract][Full Text] [Related]
10. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions.
Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Dillner J; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Maansson R; Lu S; Vuocolo S; Hesley TM; Saah A; Barr E; Haupt RM
Cancer Prev Res (Phila); 2009 Oct; 2(10):868-78. PubMed ID: 19789295
[TBL] [Abstract][Full Text] [Related]
11. Chapter 17: Genital human papillomavirus infections--current and prospective therapies.
Stanley M
J Natl Cancer Inst Monogr; 2003; (31):117-24. PubMed ID: 12807955
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic human papillomavirus vaccines: current clinical trials and future directions.
Hung CF; Ma B; Monie A; Tsen SW; Wu TC
Expert Opin Biol Ther; 2008 Apr; 8(4):421-39. PubMed ID: 18352847
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of human papillomavirus vaccines: a systematic quantitative review.
Medeiros LR; Rosa DD; da Rosa MI; Bozzetti MC; Zanini RR
Int J Gynecol Cancer; 2009 Oct; 19(7):1166-76. PubMed ID: 19823051
[TBL] [Abstract][Full Text] [Related]
14. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.
Schwarz TF
Adv Ther; 2009 Nov; 26(11):983-98. PubMed ID: 20024678
[TBL] [Abstract][Full Text] [Related]
15. [What should be known for the introduction of an HPV vaccine?].
Muñoz N; Jacquard AC
Presse Med; 2008 Oct; 37(10):1377-90. PubMed ID: 18786806
[TBL] [Abstract][Full Text] [Related]
16. Prevention of human papillomavirus infections and associated diseases by vaccination: a new hope for global public health.
Harper DM
Public Health Genomics; 2009; 12(5-6):319-30. PubMed ID: 19684444
[TBL] [Abstract][Full Text] [Related]
17. Advances in therapeutic vaccines for treating human papillomavirus-related cervical intraepithelial neoplasia.
Barra F; Della Corte L; Noberasco G; Foreste V; Riemma G; Di Filippo C; Bifulco G; Orsi A; Icardi G; Ferrero S
J Obstet Gynaecol Res; 2020 Jul; 46(7):989-1006. PubMed ID: 32390320
[TBL] [Abstract][Full Text] [Related]
18. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
Jenkins D
Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
[TBL] [Abstract][Full Text] [Related]
19. THERAPEUTIC USE OF HUMAN PAPILLOMAVIRUS VACCINES IN CERVICAL LESIONS.
Castro-Eguiluz D; Barquet-Muñoz SA; Arteaga-Gómez AC; Salcedo Hernández RA; Rodríguez-Trejo A; Gallardo-Rincón D; Serrano-Olvera JA; Aranda-Flores C
Rev Invest Clin; 2020; 72(4):239-249. PubMed ID: 33064708
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus vaccines.
Schmiedeskamp MR; Kockler DR
Ann Pharmacother; 2006; 40(7-8):1344-52. PubMed ID: 16849621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
